Health
Breakthrough Cancer Vaccine Shows 90% Effectiveness in Large-Scale Clinical Trial
A personalized mRNA cancer vaccine developed by BioNTech has shown 90% effectiveness in preventing recurrence across multiple cancer types in a Phase III trial involving 8,000 patients.